Year: 2020
Resolve Therapeutics announces clinically meaningful improvement in patients with Systemic lupus erythematosus in Phase 2a clinical trial
Resolve Therapeutics, pioneering first-in-class, targeted, safe therapies for underserved autoimmune diseases, today announced results from its Phase 2a study of RSLV-132 in patients with Systemic lupus erythematosus (SLE). Sixty-six patients diagnosed with SLE and a CLASI score of ≥ 10 at screening were enrolled into the study at 19 clinical
Read MoreResolve Therapeutics publishes positive Sjogren’s syndrome clinical trial results
Resolve Therapeutics, pioneering first-in-class, targeted, safe therapies for underserved autoimmune diseases, today announced publication of results from its Phase 2 study of RSLV-132 for the treatment of primary Sjogren’s syndrome (pSS). The work was published in the leading rheumatology journal, Arthritis and Rheumatology (doi.org/10.1002/art.41489). The Phase 2 study demonstrated a
Read More
NorthSea Therapeutics doses first patient in Phase 1 trial of SEFA-1024 in dyslipidemia and further expands its clinical pipeline
NST becomes a multi-asset clinical development company, beyond NASH Pre-clinical studies have demonstrated broad and marked beneficial effects of SEFA-1024 on non-HDL cholesterol, triglycerides, and HDL cholesterol and glycemic control A third clinical development program, SEFA 6179, for treating Intestinal Failure- Associated Liver Disease (IFALD) will start Phase 1 studies
Read More
Amarisoft and Dali Wireless Collaborate to Deliver Open RAN Based 4G and 5G Solutions
Interoperability and co-marketing initiatives will bring new options for enterprises, and mobile network operators deploying in-building cellular solutions Menlo Park, California and Paris, France – February 11, 2020 – Dali Wireless, a global leader in wireless fronthaul innovation for virtual RAN, and Amarisoft, a pioneer in software centric 4G LTE
Read More
ProterixBio licenses COVID-19 serology test from Massachusetts General Hospital
Billerica, MA, July 1, 2020: ProterixBio, Inc. today announced completing a licensing agreement with the Massachusetts General Hospital for a COVID-19 serology assay. The assay was developed and validated by researchers at the Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University which is a joint
Read More
Oppilan Pharma Announces Positive Phase 1 Data for its Ulcerative Colitis Drug OPL-002 at Digestive Disease Week 2020 Virtual Scientific Program
Potential best-in-class profile for an oral sphingosine-1-phosphate receptor modulator – Dose-dependent reduction in circulating lymphocytes –– Rapid lymphocyte recovery after cessation of dosing –– Phase 2 study in ulcerative colitis patients in 4Q 2020 – ENCINITAS, California and Cambridge, United Kingdom, June 23, 2020 – Oppilan Pharma, Ltd., a clinical-stage
Read More
Zoll TherOx Receives CE Mark Approval for Supersaturated Oxygen Therapy
View Full Press Release >>
Read MoreFDA Approves Next-Generation ZOLL® TherOx System for Widowmaker Heart Attack Patients First
View Full Press Release >>
Read More
Perceptimed Founder Jacobs To Speak At Bio2device Group Event
PERCEPTIMED FOUNDER JACOBS TO SPEAK AT BIO2DEVICE GROUP EVENT MOUNTAIN VIEW, CA – April 25, 2014 – “Preventing Drug-Related Patient Injury and Death with Advanced, Cost-Effective Technology” is the topic Alan Jacobs, M.D., Ph.D., CEO and founder of PerceptiMed, will address at the Bio2Device lecture. The lecture will take place
Read MorePerceptimed Awarded NIH Development Grant
PERCEPTIMED AWARDED $1.5M NIH DEVELOPMENT GRANT MOUNTAIN VIEW, CA – PerceptiMed, Inc., was awarded a $1.5 million grant from the National Institutes of Health (NIH) to develop and test a secure, individual medication system for long-term care facilities. Dr. Alan Jacobs, CEO and founder of PerceptiMed will serve as
Read MoreScripps La Jolla First In U.S. To Use ZOLL’s FDA-Approved SuperSaturated Oxygen Therapy On Patients Suffering from Widowmaker Heart Attacks
View Full Press Release >>
Read MoreNorthSea Therapeutics Announces US $40 Million Series B Financing to Complete Phase IIb ICONA study in NASH and to Advance Two Additional SEFAs into the Clinic
Two new US investors; lead investor, venBio Partners and Sofinnova Investments, join syndicate of existing investors Richard Gaster, M.D., Ph.D., Principal at venBio Partners, and Maha Katabi, Ph.D., CFA, Partner at Sofinnova Investments join the Board Proceeds will be used to progress the SEFA development pipeline: Completion of Phase 2b
Read More